LEAP, an advanced arrhythmia assay on the Maestro multiwell MEA system: Coffee Break Webinar

Learn more: https://www.axionbiosystems.com/appli...

The inability to predict a drug’s cardiovascular liability prior to clinical trials or launch has resulted in numerous costly late stage drug development failures and market withdrawals. The aim of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is to update the existing cardiac safety testing paradigm to better evaluate arrhythmia risk. One proposed test of the CiPA panel is a microelectrode array (MEA) assay that tracks drug-induced changes to beating heart cells in a dish. In this webinar, Dr. Daniel Millard, discusses advances in arrhythmia detection to support next-generation CM-MEA assays, using the Maestro multiwell MEA system.

What is a multiwell MEA assay?
Axion’s microelectrode array (MEA), also known as multielectrode array, plates have a grid of tightly spaced electrodes embedded in the culture surface of each well. Electrically active cells, such as cardiomyocytes, can be cultured over the electrodes. Over time, as the cultures become established, they form cohesive networks and present an electrophysiological profile. The resulting electrical activity from the beating cardiomyocytes is captured from each electrode on a microsecond timescale providing both temporally and spatially precise data.